Ozempic for CKD and heart disease The FLOW phase 3b clinical trial (NCT03819153) demonstrated that when Ozempic 1 mg injection was used in adults with type 2 diabetes and CKD, Ozempic demonstrated: 24% reduced the risk of kidney disease progression, kidney failure, and cardiovascular death at 3 years when compared to placebo
La dosis habitual es de 50-100 mg/kg/da, tanto en nios como en adultos, distribuida en 2 o 3 tomas por da
GSH/GSSG What They Are and Why They Matter Glutathione is the primary intracellular antioxidant, existing as reduced glutathione (GSH) and its oxidized form (GSSG)
Nyholm, B
doi: 10.1038/aps.2016.21 Summary Keywords metformin, intestinal microbiota, gastrointestinal mucosal barrier, SCFAs, bile acid metabolism Citation Wang Y, Jia X and Cong B (2024) Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity A Phase 2 Trial